NCT05021367 - A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

October 31, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

TQB3823 tablets

TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Cen, Guangzhou